Illumina exhibits better profitability ratios than many of its peers, which indicates that the company could continue to invest in its operations. In Q3 2025, ILMN raised its EPS to $4.65-$4.75, ...

Genomics company Illumina (NASDAQ:ILMN) reported Q1 CY2026 results , with sales up 4.8% year on year to $1.09 billion. The ...

Genomics company Illumina (NASDAQ:ILMN) reported Q1 CY2026 results , with sales up 4.8% year on year to $1.09 billion. The ...

Illumina (NASDAQ:ILMN) reported first-quarter 2026 results that came in above its guidance range on revenue, margins, and earnings per share, supported by strength in clinical demand and ...

Illumina will sequence up to 4,000 unique individual animals across 1,300 species, unlock genomic insights from 50-year-old biological samples Sequencing connects decades of preserved biodiversity ...

TEM and ILMN battle in precision oncology, but stronger stock gains, valuation and earnings outlook position ILMN as the more compelling pick now.

San Diego-based Illumina, a global leader in genomic sequencing technology, unveiled its latest machines that could make analyzing genetics cheaper, more efficient and more accessible to researchers.

San Diego’s Illumina is the world leader in gene sequencing technology — the ability to read and record DNA. Now, the billion-dollar company is buying another in a bid to expand its portfolio in ...

SAN DIEGO, Feb. 3, 2026 — Illumina (NASDAQ: ILMN) today announced a sequencing agreement with the San Diego Zoo Wildlife Alliance (SDZWA)’s Frozen Zoo®. The 50-year-old biobank is the world’s most ...